Phase III Trial Comparing Radical Radiotherapy With and Without Cisplatin Chemotherapy in Patients With Advanced Squamous Cell Cancer of the Cervix

2002 ◽  
Vol 20 (4) ◽  
pp. 966-972 ◽  
Author(s):  
R. Pearcey ◽  
M. Brundage ◽  
P. Drouin ◽  
J. Jeffrey ◽  
D. Johnston ◽  
...  
Keyword(s):  
Squamous Cell ◽  
Squamous Cell Cancer ◽  
Cell Cancer ◽  
Survival Rates ◽  
Progression Free Survival ◽  
Lymph Node Involvement ◽  
Phase Iii ◽  
Gynecology And Obstetrics ◽  
Significant Difference ◽  
Cancer Of The Cervix

PURPOSE: To test the hypothesis that cisplatin (CDDP) administered concurrently with standard radiotherapy (RT) would improve pelvic control and survival in patients with advanced squamous cell cancer of the cervix. PATIENTS AND METHODS: A total of 259 patients with International Federation of Gynecology and Obstetrics stage IB to IVA squamous cell cervical cancer with central disease ≥ 5 cm or histologically confirmed pelvic lymph node involvement were randomized to receive RT (external-beam RT plus brachytherapy) plus weekly CDDP chemotherapy (40 mg/m2) (arm 1) or the same RT without chemotherapy (arm 2). RESULTS: A total of 253 patients were available for analysis. Median follow-up was 82 months. No significant difference was found in progression-free survival (P = .33). No significant difference in 3- and 5-year survival rates was found (69% v 66% and 62% v 58%, respectively; P = .42). The hazard ratio for survival (arm 2 to arm 1) was 1.10 (95% confidence interval, 0.75 to 1.62). CONCLUSION: This study did not show a benefit to either pelvic control or survival by adding concurrent weekly CDDP chemotherapy in a dose of 40 mg/m2 to radical RT as given in this trial. Careful attention to RT details is important for achieving optimum outcome for patients with this disease.

Prolonged stabilization of progressive squamous cell cancer of the cervix with interferon-α and 13-cis-retinoic acid

1996 ◽  
Vol 7 (7) ◽  
pp. 800-804 ◽  
Author(s):  
Surintip Piamsomboon ◽  
Wichai Termrungruanglert ◽  
Andrzej P Kudelka ◽  
Creighton L Edwards ◽  
Ralph S Freedman ◽  
...  
Keyword(s):  
Retinoic Acid ◽  
Squamous Cell ◽  
Squamous Cell Cancer ◽  
Cell Cancer ◽  
Interferon Α ◽  
Cancer Of The Cervix

scholarly journals Practical Applications of In-Office Fiberoptic Transnasal Esophagoscopy in the Initial Evaluation of Patients with Squamous Cell Cancer of the Head and Neck

2013 ◽  
Vol 92 (9) ◽  
pp. 450-455 ◽  
Author(s):  
Robert W. Dolan ◽  
Timothy D. Anderson
Keyword(s):  
Head And Neck ◽  
Squamous Cell ◽  
Incidental Findings ◽  
Squamous Cell Cancer ◽  
Cell Cancer ◽  
Tongue Base ◽  
Unknown Primary ◽  
Initial Visit ◽  
Esophageal Cancers ◽  
Significant Difference

We conducted a study to analyze the effectiveness of trans-nasal esophagoscopy (TNE) as an alternative to operative endoscopy (OE) for the evaluation of primary head and neck cancers and for the surveillance of synchronous esophageal cancers. Our study population was made up of 96 consecutively presenting patients—75 men and 21 women, aged 45 to 88 years (mean: 64)—who were treated at our institution for squamous cell cancer of the head and neck. Of this group, 42 patients had been evaluated with TNE and 54 with OE. More OEs were performed inpatients with an unknown primary (26 vs. 3). Incidental findings on TNE included 3 cases of gastritis, 2 cases each of hiatal hernia and esophagitis, 1 case of Barrett esophagus, and 1 inlet patch. No incidental findings were reported during OE. Primary cancers were biopsied by TNE through a port on the endoscope in 4 patients; 2 of these cancers were in the tongue base, 1 in the hypopharynx, and 1 in the aryepiglottic fold. After the initial visit, patients in the TNE group waited significantly fewer days for their endoscopy than did those in the OE group (median: 6.5 vs. 16; p < 0.05). Conversely, patients in the OE group waited significantly fewer days for treatment following endoscopy (median: 12 vs. 20; p < 0.05). However, there was no significant difference between the TNE patients and the OE patients in the total number of days comprising the their entire course of management, from the initial visit to definite treatment (median: 27.5 and 33 days, respectively; p = 0.7). We conclude that TNE is a reasonable alternative to OE for the initial screening for synchronous esophageal cancers inpatients with squamous cancers of the head and neck. OE is preferred for the initial workup of unknown primary cancers and for large tongue base cancers. The rate of detection of clinically relevant incidental findings is higher with TNE. Biopsy is possible during TNE for all subsites within the upper aerodigestive tract.

Phase II randomized trial of cisplatin chemotherapy regimens in the treatment of recurrent or metastatic squamous cell cancer of the cervix: a Southwest Oncology Group Study.

1987 ◽  
Vol 5 (11) ◽  
pp. 1791-1795 ◽  
Author(s):  
D S Alberts ◽  
R Kronmal ◽  
L H Baker ◽  
D L Stock-Novack ◽  
E A Surwit ◽  
...  
Keyword(s):  
Randomized Trial ◽  
Mitomycin C ◽  
Phase Ii ◽  
Squamous Cell ◽  
Squamous Cell Cancer ◽  
Cell Cancer ◽  
Response Rates ◽  
Oncology Group ◽  
Southwest Oncology Group ◽  
Cancer Of The Cervix

Cisplatin has proven to be the most active single agent in the treatment of metastatic and recurrent squamous cell cancer of the cervix. In a previous southwest Oncology Group (SWOG) pilot study, the addition of cisplatin to a mitomycin-C, vincristine, and bleomycin (MVB) regimen resulted in a relatively high percentage of durable complete responses. To gain more experience with cisplatin-based chemotherapy regimens, the SWOG initiated a phase II randomized trial of cisplatin, mitomycin-C plus cisplatin (MC), and MVB plus cisplatin (MVBC) in 119 patients with advanced squamous cell cancer of the cervix and no prior chemotherapy exposure. Because of slow patient accrual early in the trial, the cisplatin arm was discontinued. Five patients were declared ineligible according to protocol criteria. The three treatment groups were relatively well matched for age, prior radiation exposure, and sites of measurable disease. The overall objective response rates for cisplatin, MC, and MVBC treated patients were 33%, 25%, and 22%, respectively. Median response durations were greater than 6 months. Median survival durations associated with cisplatin, MC, and MVBC treatment were 17.0, 7.0, and 6.9 months, respectively. There were no drug-related deaths. Severe or life-threatening leukopenia and thrombocytopenia were observed in 18% to 24% of patients treated with MVBC and MC, but in none of those receiving cisplatin alone. We conclude that the low response rates and short durations of both response and survival observed in patients randomized to the two chemotherapy combinations suggest that only enhanced toxicity was gained through the addition of mitomycin-C or MVB to cisplatin in patients with advanced cervix cancer.

Novel Insight: CUEDC2 Expression of Potential Prognostic Value in Esophageal Squamous Cell Cancer

2020 ◽  
Author(s):  
Jun-bo Xiao ◽  
Rong Wu ◽  
Xuemei Peng ◽  
Bin Chen ◽  
Yan-qiu Zhang ◽  
...  
Keyword(s):  
Squamous Cell ◽  
Squamous Cell Cancer ◽  
Human Life ◽  
Cell Cancer ◽  
Tumor Grade ◽  
Clinicopathological Characteristics ◽  
Esophageal Squamous Cell Cancer ◽  
Clinicopathological Parameters ◽  
Significant Difference ◽  
The Difference

Abstract Background Esophageal squamous cell cancer (ESCC) poses serious threats to human life. Hence, the search for effective bio-markers to predict the occurrence and development of ESCC is of emerging significance.Methods We used immunohistochemistry to semi-quantitatively detect CUEDC2 expression in 50 ESCC cases and 20 adjacent tissues, analyzing the relationship with clinicopathological parameters and prognosis outcomes. Additionally, investigating the differences between CUEDC2 and CD68 in ESCC.Result CUEDC2 expression was higher in 9 ESCC tissues and lower in 41 ESCC tissues. Whereas, CUEDC2 expression was higher in 11 adjacent tissues and lower of the rest 9 cases, and the differences were statistically significant (P<0.05).CUEDC2 and ESCC clinicopathological characteristics exerted no significant difference (P>0.05). Via the Kaplan-Meier method, CUEDC2 and tumor grade demonstrated an impact on ESCC prognosis ( P<0.05). By double-immunofluorescence, there was an expression difference between CD68 and CUEDC2, and the difference was statistically significant (P<0.05). There showed co-localization of CUEDC2 and CD68 fluorescence.Conclusion CUEDC2 was relatively lower expressed in ESCC and higher in adjacent tissues. There was no significant difference between CUEDC2 and ESCC clinicopathological characteristics.CUEDC2 and tumor grade presented an impact on ESCC prognosis. There might be an interaction between CD68 and CUEDC2.

Sign in / Sign up

Export Citation Format

Share Document